Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00192829
First received: September 13, 2005
Last updated: April 10, 2007
Last verified: March 2007
  Purpose

The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).


Condition Intervention
Non-Small Cell Lung Carcinoma
Venous Thromboembolism
Procedure: Blood sample withdrawal

Study Type: Observational
Study Design: Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 100
Study Start Date: June 2005
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of NSCLC.
  • normal serum bilirubin
  • informed concent to participate in the study

Exclusion Criteria:

  • anticoagulant therapy
  • infectious disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00192829

Contacts
Contact: Galit Sarig, Ph.D +972-4-8543503 g_sarig@rambam.health.gov.il
Contact: Nissim Haim, M.D

Locations
Israel
Hematology Laboratory Recruiting
Haifa, Israel
Contact: Galit Sarig, Ph.D    +972-4-8543523    g_sarig@rambam.health.gov.il   
Principal Investigator: Galit Sarig, Ph.D         
Oncology Institution, Rambam Health Campus Recruiting
Haifa, Israel
Contact: Nissim Haim, M.D       n_haim@rambam.health.gov.il   
Principal Investigator: Nissim Haim, M.D         
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Galit Sarig, Ph.D Rambam Health Care Campus
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00192829     History of Changes
Other Study ID Numbers: Thrombosis and cancer.CTIL
Study First Received: September 13, 2005
Last Updated: April 10, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:
Lung cancer
Thrombosis
Hypercoagulable

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Bronchial Neoplasms
Carcinoma, Bronchogenic
Cardiovascular Diseases
Embolism and Thrombosis
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Thrombosis
Vascular Diseases

ClinicalTrials.gov processed this record on October 23, 2014